NYSE:AGN - Allergan Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$160.22 +3.66 (+2.34 %)
(As of 01/18/2019 04:00 PM ET)
Previous Close$160.22
Today's Range$156.32 - $160.66
52-Week Range$125.84 - $197.00
Volume2.89 million shs
Average Volume2.48 million shs
Market Capitalization$52.81 billion
P/E Ratio9.80
Dividend Yield1.84%
Beta1.32
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, and anti-infective therapeutic categories. It also provides breast implants and tissue expanders; RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis; ocular implants; and Kybella, a non-surgical treatment for submental fullness. In addition, the company develops therapies for non-alcoholic steatohepatitis and other liver diseases; treatments for neurodegenerative disorders, including Alzheimer's disease; small molecule therapeutics that target inflammatory and fibrotic diseases; and delivery system and botulinum toxin-based prescription products. It has collaboration, option, and license agreement with Lyndra, Inc.; strategic alliance and option agreement with Editas Medicine, Inc.; and licensing agreements with Assembly Biosciences, Inc. MedImmune, and Heptares Therapeutics, Ltd. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.

Receive AGN News and Ratings via Email

Sign-up to receive the latest news and ratings for AGN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP01849010
Phone862-261-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$15.94 billion
Cash Flow$41.0821 per share
Book Value$207.19 per share

Profitability

Net Income$-4,125,500,000.00

Miscellaneous

Employees17,800
Market Cap$52.81 billion
OptionableOptionable

Allergan (NYSE:AGN) Frequently Asked Questions

What is Allergan's stock symbol?

Allergan trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."

How often does Allergan pay dividends? What is the dividend yield for Allergan?

Allergan announced a quarterly dividend on Friday, October 26th. Shareholders of record on Tuesday, November 13th will be given a dividend of $0.72 per share on Friday, December 14th. This represents a $2.88 dividend on an annualized basis and a yield of 1.80%. The ex-dividend date of this dividend is Friday, November 9th. View Allergan's Dividend History.

How will Allergan's stock buyback program work?

Allergan declared that its Board of Directors has approved a stock buyback program on Tuesday, September 26th 2017, which permits the company to repurchase $2,000,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to repurchase up to 2.8% of its stock through open market purchases. Stock repurchase programs are often a sign that the company's management believes its shares are undervalued.

How were Allergan's earnings last quarter?

Allergan plc (NYSE:AGN) released its earnings results on Tuesday, October, 30th. The company reported $4.25 EPS for the quarter, beating the Zacks' consensus estimate of $4.04 by $0.21. The business earned $3.91 billion during the quarter, compared to the consensus estimate of $3.89 billion. Allergan had a net margin of 14.50% and a return on equity of 8.44%. The company's revenue for the quarter was down 3.0% compared to the same quarter last year. During the same quarter last year, the company earned $4.15 EPS. View Allergan's Earnings History.

When is Allergan's next earnings date?

Allergan is scheduled to release their next quarterly earnings announcement on Tuesday, January 29th 2019. View Earnings Estimates for Allergan.

How can I listen to Allergan's earnings call?

Allergan will be holding an earnings conference call on Tuesday, January 29th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8772517980.

What guidance has Allergan issued on next quarter's earnings?

Allergan updated its FY18 earnings guidance on Tuesday, October, 30th. The company provided earnings per share (EPS) guidance of $16.20-16.60 for the period, compared to the Thomson Reuters consensus estimate of $16.38. The company issued revenue guidance of $15.55-15.7 billion, compared to the consensus revenue estimate of $15.63 billion.Allergan also updated its FY 2018 guidance to $16.20-16.60 EPS.

What price target have analysts set for AGN?

21 Wall Street analysts have issued twelve-month target prices for Allergan's shares. Their predictions range from $164.00 to $265.00. On average, they expect Allergan's stock price to reach $211.2778 in the next year. This suggests a possible upside of 31.9% from the stock's current price. View Analyst Price Targets for Allergan.

What is the consensus analysts' recommendation for Allergan?

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allergan in the last year. There are currently 4 hold ratings and 17 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Allergan.

What are Wall Street analysts saying about Allergan stock?

Here are some recent quotes from research analysts about Allergan stock:
  • 1. According to Zacks Investment Research, "Allergan’s products like Botox and Linzess and new products such as Viberzi, Namzaric and Vraylar support sales. It also boasts a strong branded pipeline. Biosimilars also represent significant opportunity. However, while we remain optimistic about the company’s growth prospects, Allergan faces loss of exclusivity for many key products. While generic versions of Alzheimer’s treatment, Namenda XR and Estrace cream have been launched, that of blockbuster dry-eye drug, Restasis, is expected to be launched soon. Sales of these products are expected to decline significantly with the introduction of generics. Also, new competition for key growth drivers, Botox, Restasis and Linzess, is a concern. Particularly, the entry of CGRP antibodies in 2018 may have a negative impact on sales of Botox Therapeutics, mainly for the chronic migraine indication. Allergan’s shares have underperformed the industry in the past three months." (1/3/2019)
  • 2. Cantor Fitzgerald analysts commented, "We rate AGN Neutral and have a 12-month price target of $180. We think that Allergan is one the highest-quality and most-innovative companies in the Pharma industry. That said, we don’t see a lot of upside to consensus expectations in the near term, which is why we are on the sidelines for now. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $180." (9/14/2018)
  • 3. Mizuho analysts commented, "We note that Mylan has invalidated Restasis patents, and Allergan mgmt. noted that two other generic manufacturers (Teva and Akorn that have not settled) could also launch Restasis generics if their applications are FDA-approved. We know that Allergan separately entered into five other generic settlements, according to its 1Q:18 10-Q filing. No news from Mylan or the others would be good news to Allergan, in our view." (7/30/2018)

Has Allergan been receiving favorable news coverage?

Headlines about AGN stock have been trending somewhat positive this week, according to InfoTrie. The research group identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Allergan earned a daily sentiment score of 0.9 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an effect on the company's share price in the near term.

Who are some of Allergan's key competitors?

Who are Allergan's key executives?

Allergan's management team includes the folowing people:
  • Mr. Brenton L. Saunders, Chairman, Pres & CEO (Age 48)
  • Mr. William Meury, Exec. VP & Chief Commercial Officer (Age 50)
  • Dr. C. David Nicholson, Exec. VP and Chief R&D Officer (Age 63)
  • Mr. Matthew M. Walsh, Exec. VP & CFO (Age 51)
  • Mr. Wayne R. Swanton, Exec. VP of Global Operations (Age 50)

Who are Allergan's major shareholders?

Allergan's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Retirement Systems of Alabama (0.12%), Cacti Asset Management LLC (0.06%), Confluence Investment Management LLC (0.04%), Nisa Investment Advisors LLC (0.03%), Advisors Capital Management LLC (0.02%) and Arvest Bank Trust Division (0.02%). Company insiders that own Allergan stock include Brent L Saunders, Chris W Bodine, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado, Matthew M Walsh, Nesli Basgoz, Paul Bisaro and William Meury. View Institutional Ownership Trends for Allergan.

Which major investors are selling Allergan stock?

AGN stock was sold by a variety of institutional investors in the last quarter, including Confluence Investment Management LLC, Gateway Investment Advisers LLC, Gibraltar Capital Management Inc., Horan Capital Management, Gofen & Glossberg LLC IL, RNC Capital Management LLC, Vision Capital Management Inc. and Neville Rodie & Shaw Inc.. View Insider Buying and Selling for Allergan.

Which major investors are buying Allergan stock?

AGN stock was bought by a variety of institutional investors in the last quarter, including Retirement Systems of Alabama, Meeder Asset Management Inc., Contravisory Investment Management Inc., Cumberland Advisors Inc., Personal Capital Advisors Corp, Kempner Capital Management Inc., Diversified Trust Co and Steward Partners Investment Advisory LLC. Company insiders that have bought Allergan stock in the last two years include Brent L Saunders, Chris W Bodine, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado and Matthew M Walsh. View Insider Buying and Selling for Allergan.

How do I buy shares of Allergan?

Shares of AGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Allergan's stock price today?

One share of AGN stock can currently be purchased for approximately $160.22.

How big of a company is Allergan?

Allergan has a market capitalization of $52.81 billion and generates $15.94 billion in revenue each year. The company earns $-4,125,500,000.00 in net income (profit) each year or $16.35 on an earnings per share basis. Allergan employs 17,800 workers across the globe.

What is Allergan's official website?

The official website for Allergan is http://www.allergan.com.

How can I contact Allergan?

Allergan's mailing address is CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK, DUBLIN L2, D17 E400. The company can be reached via phone at 862-261-7000 or via email at [email protected]


MarketBeat Community Rating for Allergan (NYSE AGN)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  1,278 (Vote Outperform)
Underperform Votes:  563 (Vote Underperform)
Total Votes:  1,841
MarketBeat's community ratings are surveys of what our community members think about Allergan and other stocks. Vote "Outperform" if you believe AGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel